Amissa Health
Amissa Health is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Amissa Health is a technology company.
Amissa Health is a women's health tech company that builds digital tools combining biometric data from wearables with self-reported symptoms to deliver personalized insights for menopause and perimenopause care.[1][5] It serves clinicians and patients by quantifying symptoms like sleep, mood, and vitals to spot patterns between doctor visits, addressing care gaps where 85% of women experience disruptive symptoms but 73% lack treatment.[1][5] Originally focused on Alzheimer's research, Amissa pivoted to midlife women's health after uncovering links between menopause and dementia, enabling faster, data-driven prescribing and better outcomes.[1][2]
The platform generates 200,000 times more real-world data than clinician visits, supporting individualized care plans and research scalability.[1][4] With products like AmissaCare™ for clinicians and patient-facing tracking, it targets the 1.3 million U.S. women entering menopause annually, partnering with OB/GYNs, menopause specialists, and institutions like Washington University.[1][4][5]
Amissa Health was founded in 2017 in Charlotte, NC, by Jon A. Corkey (President and Founder) and early leaders like Colby Ford (Head of Product), initially to support Alzheimer’s research through scalable wearable data collection.[1][3] The company enabled U.S. institutions to gather real-world data at scale, including an NIH SBIR grant in 2024 with Washington University in St. Louis for machine learning models detecting early Alzheimer’s signs via behaviors in older adults.[1]
Pivoting in recent years, Amissa shifted to women's health after discovering scientific links between menopause hormonal changes and dementia—two-thirds of dementia patients are women.[1] This evolution built on their core tech for easy wearable integration (e.g., Apple Watch), compliance monitoring, and data analysis, humanizing care for vulnerable populations like Alzheimer's patients and now perimenopausal women.[1][4]
Amissa rides the wave of digital biomarkers in women's health, quantifying perimenopause—a phase lacking measurable markers despite its links to dementia, heart health, and workforce dropout (1 in 5 women).[1][5] Timing aligns with surging demand: menopause tech funding and awareness spiked post-2020, fueled by clinician shortages and wearable adoption (e.g., Apple Watch ubiquity).[1][4]
Market forces favor Amissa, including NIH support for brain health, growing insurer interest in preventive midlife care, and AI-driven personalization in femtech.[1][2] It influences the ecosystem by enabling research scalability—easing data collection for universities/hospitals—and bridging menopause-dementia gaps, potentially reducing the $1T+ global dementia burden through early intervention.[1]
Amissa Health is poised to lead menopause care digitization, expanding from Alzheimer's roots into a full midlife health platform with AI models predicting symptom trajectories and long-term risks.[1] Next steps likely include broader wearable integrations, clinician partnerships (e.g., Atrium Health), and global scaling as femtech matures amid regulatory tailwinds like FDA biomarker validations.
Shaping trends—AI in wearables, menopause equity advocacy, and preventive health economics—will amplify its momentum, evolving Amissa from data collector to care standard-setter. This positions it to empower the 1.3M annual U.S. entrants into menopause with tools that make invisible symptoms visible, faster.